LONDON, ONTARIO--(Marketwire - September 24, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE: COT), announced today that it has entered into an agreement with a major pharmaceutical company to advance up to six drug candidates from COTI’s HIV-1 integrase inhibitor program, identified using its CHEMSAS® drug discovery process.
